Skip to main content

Compare Stocks

Date Range: 

 Calliditas Therapeutics AB (publ)Emisphere TechnologiesKadmonXenon PharmaceuticalsVeru
SymbolNASDAQ:CALTOTCMKTS:EMISNASDAQ:KDMNNASDAQ:XENENASDAQ:VERU
Price Information
Current Price$27.12$7.81$3.48$16.81$7.25
52 Week RangeBuyN/ABuyBuyBuy
MarketRank™
Overall Score1.30.91.81.61.4
Analysis Score3.50.03.53.53.5
Community Score2.62.63.12.72.8
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.71.70.0
Earnings & Valuation Score0.60.00.60.00.6
Analyst Ratings
Consensus RecommendationBuyN/ABuyBuyBuy
Consensus Price Target$40.80N/A$12.75$25.25$19.20
% Upside from Price Target50.44% upsideN/A266.38% upside50.21% upside164.83% upside
Trade Information
Market Cap$677.21 million$673.08 million$613.09 million$688.59 million$521.36 million
BetaN/A1.381.681.20.71
Average Volume39,62375,7433,325,586176,6923,539,451
Sales & Book Value
Annual Revenue$19.56 millionN/A$5.09 million$6.83 million$42.59 million
Price / Sales34.62N/A117.58100.8212.24
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/A$0.95 per share$2.99 per share$0.43 per share
Price / Book∞N/A3.665.6216.86
Profitability
Net Income$-3,450,000.00N/A$-61,370,000.00$-41,600,000.00$-18,970,000.00
EPS($0.19)N/A($0.74)($1.54)($0.11)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/A∞N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-768.36%-102.25%-44.55%
Return on Equity (ROE)-26.80%N/A-85.07%-21.76%-23.72%
Return on Assets (ROA)-25.38%N/A-46.46%-16.08%-13.80%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.02%N/AN/A
Current Ratio23.46%N/A5.76%9.83%1.83%
Quick Ratio23.46%N/A5.76%9.83%1.38%
Ownership Information
Institutional Ownership Percentage11.85%0.02%94.78%79.90%23.32%
Insider Ownership PercentageN/A72.90%2.95%8.35%26.10%
Miscellaneous
Employees346127123339
Shares Outstanding24.97 million86.18 million171.97 million40.96 million71.91 million
Next Earnings DateN/AN/A8/5/2021 (Estimated)8/5/2021 (Estimated)8/12/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
FDA accepts application for tadalafil/finasteride combo capsule for BPH - Urology TimesFDA accepts application for tadalafil/finasteride combo capsule for BPH - Urology Times
urologytimes.com - May 14 at 3:34 AM
Announcing: Veru (NASDAQ:VERU) Stock Soared An Exciting 440% In The Last Five Years - NasdaqAnnouncing: Veru (NASDAQ:VERU) Stock Soared An Exciting 440% In The Last Five Years - Nasdaq
nasdaq.com - May 14 at 3:34 AM
Analysts Offer Insights on Healthcare Companies: EDAP TMS (EDAP), Veru (VERU) and Kamada (KMDA) - Smarter AnalystAnalysts Offer Insights on Healthcare Companies: EDAP TMS (EDAP), Veru (VERU) and Kamada (KMDA) - Smarter Analyst
smarteranalyst.com - May 13 at 12:52 PM
Veru (NASDAQ:VERU) Posts Earnings Results, Misses Expectations By $0.01 EPSVeru (NASDAQ:VERU) Posts Earnings Results, Misses Expectations By $0.01 EPS
americanbankingnews.com - May 13 at 12:34 PM
Veru, Inc. (VERU) CEO Mitchell Steiner on Q2 2021 Results - Earnings Call Transcript - Seeking AlphaVeru, Inc. (VERU) CEO Mitchell Steiner on Q2 2021 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 12 at 8:44 PM
Veru Inc. (VERU) Q2 2021 Earnings Call Transcript - AlphaStreetVeru Inc. (VERU) Q2 2021 Earnings Call Transcript - AlphaStreet
news.alphastreet.com - May 12 at 3:44 PM
Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates - Yahoo FinanceVeru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 12 at 3:44 PM
Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue EstimatesVeru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - May 12 at 3:44 PM
$VERU Veru Reports Q2 Loss Per Share Of $0.04 - CML News$VERU Veru Reports Q2 Loss Per Share Of $0.04 - CML News
cmlviz.com - May 12 at 10:43 AM
Veru: Q2 Earnings Insights - BenzingaVeru: Q2 Earnings Insights - Benzinga
benzinga.com - May 12 at 10:43 AM
Veru Reports Strong Second-Quarter Financial Results Based - GlobeNewswireVeru Reports Strong Second-Quarter Financial Results Based - GlobeNewswire
globenewswire.com - May 12 at 10:43 AM
Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription RevenuesVeru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues
finance.yahoo.com - May 12 at 10:43 AM
What Makes ING (ING) a Good Fit for "Trend Investing" - NasdaqWhat Makes ING (ING) a Good Fit for "Trend Investing" - Nasdaq
nasdaq.com - May 11 at 1:32 PM
My Plea to Investors Right Now - NasdaqMy Plea to Investors Right Now - Nasdaq
nasdaq.com - May 10 at 8:57 PM
Builders FirstSource (BLDR) Buys Johns Lumber, Boosts Presence - NasdaqBuilders FirstSource (BLDR) Buys John's Lumber, Boosts Presence - Nasdaq
nasdaq.com - May 10 at 3:55 PM
Why Veru (VERU) Might Surprise This Earnings Season - Yahoo FinanceWhy Veru (VERU) Might Surprise This Earnings Season - Yahoo Finance
finance.yahoo.com - May 10 at 3:55 PM
Why Veru (VERU) Might Surprise This Earnings SeasonWhy Veru (VERU) Might Surprise This Earnings Season
finance.yahoo.com - May 10 at 3:55 PM
Where Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Down -11.76% This Week? - InvestorsObserverWhere Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Down -11.76% This Week? - InvestorsObserver
investorsobserver.com - May 7 at 5:39 PM
Veru (NASDAQ:VERU) Trading 8.6% Higher Veru (NASDAQ:VERU) Trading 8.6% Higher
americanbankingnews.com - May 7 at 12:56 PM
Veru Inc. (NASDAQ:VERU) Forecasted to Earn FY2022 Earnings of $0.00 Per ShareVeru Inc. (NASDAQ:VERU) Forecasted to Earn FY2022 Earnings of $0.00 Per Share
americanbankingnews.com - May 7 at 11:35 AM
Veru (NASDAQ:VERU) Stock Price Down 11.9%Veru (NASDAQ:VERU) Stock Price Down 11.9%
americanbankingnews.com - May 6 at 1:54 PM
Premarket Mover: Veru Inc (VERU) Up 14.56% - InvestorsObserverPremarket Mover: Veru Inc (VERU) Up 14.56% - InvestorsObserver
investorsobserver.com - May 6 at 8:53 AM
$14.36 Million in Sales Expected for Veru Inc. (NASDAQ:VERU) This Quarter$14.36 Million in Sales Expected for Veru Inc. (NASDAQ:VERU) This Quarter
americanbankingnews.com - May 6 at 4:48 AM
Clinical News: MDMA and Therapy Significantly Benefits PTSD Patients and More - BioSpaceClinical News: MDMA and Therapy Significantly Benefits PTSD Patients and More - BioSpace
biospace.com - May 5 at 5:52 PM
Veru (VERU) Stock Rises After Enobosarm Shows Clinical Benefits in Phase 2 Trial - InvestorsObserverVeru (VERU) Stock Rises After Enobosarm Shows Clinical Benefits in Phase 2 Trial - InvestorsObserver
investorsobserver.com - May 5 at 5:52 PM
DateCompanyBrokerageAction
2/26/2021Calliditas Therapeutics AB (publ)HC WainwrightInitiated Coverage
8/18/2020Calliditas Therapeutics AB (publ)Ci CapitalReiterated Rating
7/1/2020Calliditas Therapeutics AB (publ)CitigroupInitiated Coverage
6/30/2020Calliditas Therapeutics AB (publ)Jefferies Financial GroupInitiated Coverage
6/30/2020Calliditas Therapeutics AB (publ)Stifel NicolausInitiated Coverage
3/11/2021KadmonRaymond JamesBoost Price Target
11/11/2020KadmonMizuhoInitiated Coverage
10/9/2020KadmonCantor FitzgeraldReiterated Rating
9/22/2020KadmonOppenheimerReiterated Rating
1/10/2020KadmonNomura SecuritiesInitiated Coverage
10/17/2018KadmonWBB SecuritiesUpgrade
5/13/2021Xenon PharmaceuticalsSVB LeerinkReiterated Rating
3/8/2021Xenon PharmaceuticalsNeedham & Company LLCBoost Price Target
3/5/2021Xenon PharmaceuticalsWilliam BlairReiterated Rating
8/13/2020Xenon PharmaceuticalsBloom BurtonReiterated Rating
3/24/2020Xenon PharmaceuticalsWedbushInitiated Coverage
9/20/2019Xenon PharmaceuticalsGuggenheimInitiated Coverage
12/14/2020VeruBrookline Capital ManagementBoost Price Target
3/20/2019VeruCIBCInitiated Coverage
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.